WEKO3
アイテム
{"_buckets": {"deposit": "12d6126c-1460-4743-80e1-e1c831f80b04"}, "_deposit": {"created_by": 1, "id": "81281", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "81281"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00081281", "sets": ["1"]}, "author_link": ["1005803", "1005808", "1005807", "1005809", "1005806", "1005810", "1005801", "1005800", "1005805", "1005802", "1005804"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageStart": "3652", "bibliographicVolumeNumber": "12", "bibliographic_titles": [{"bibliographic_title": "Cancers"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "In treatment-refractory cancers, tumor tissues damaged by therapy initiate the repair response; therefore, tumor tissues must be exposed to an additional burden before successful repair. We hypothesized that an agent recognizing a molecule that responds to anticancer treatment-induced tissue injury could deliver an additional antitumor agent including a radionuclide to damaged cancer tissues during repair. We selected the extracellular matrix glycoprotein tenascin-C (TNC) as such a molecule, and three antibodies recognizing human and murine TNC were employed to evaluate X-irradiation-induced changes in TNC uptake by subcutaneous tumors. TNC expression was assessed by immunohistochemical staining of BxPC-3 tumors treated with or without X-irradiation (30 Gy) for 7 days. Antibodies against TNC (3-6, 12-2-7, TDEAR) and a control antibody were radiolabeled with In and injected into nude mice having BxPC-3 tumors 7 days after X-irradiation, and temporal uptake was monitored for an additional 4 days by biodistribution and single-photon emission computed tomography with computed tomography (SPECT/CT) studies. Intratumoral distribution was analyzed by autoradiography. The immunohistochemical signal for TNC expression was faint in nontreated tumors but increased and expanded with time until day 7 after X-irradiation. Biodistribution studies revealed increased tumor uptake of all three In-labeled antibodies and the control antibody. However, a statistically significant increase in uptake was evident only for In-labeled 3-6 (35% injected dose (ID)/g for 30 Gy vs. 15% ID/g for 0 Gy at day 1, \u003c 0.01), whereas limited changes in In-labeled TDEAR2, 12-2-27, and control antibody were observed (several % ID/g for 0 and 30 Gy). Serial SPECT/CT imaging with In-labeled 3-6 or control antibody provided consistent results. Autoradiography revealed noticeably stronger signals in irradiated tumors injected with In-labeled 3-6 compared with each of the nonirradiated tumors and the control antibody. The signals were observed in TNC-expressing stroma. Markedly increased uptake of In-labeled 3-6 in irradiated tumors supports our concept that an agent, such as an antibody, that recognizes a molecule involved in tissue injury repair, such as TNC, could enhance drug delivery to tumor tissues that have undergone therapy. The combination of antibody 3-6 coupled to a tumoricidal drug and conventional therapy has the potential to achieve better outcomes for patients with refractory cancer.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "MDPI"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "33291427", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/cancers12123652", "subitem_relation_type_select": "DOI"}}]}, "item_8_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.mdpi.com/2072-6694/12/12/3652", "subitem_relation_type_select": "URI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2072-6694", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sugyo, Aya"}], "nameIdentifiers": [{"nameIdentifier": "1005800", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "B Tsuji, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "1005801", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sudo, Hitomi"}], "nameIdentifiers": [{"nameIdentifier": "1005802", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takano, Kanako"}], "nameIdentifiers": [{"nameIdentifier": "1005803", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kusakabe, Moriaki"}], "nameIdentifiers": [{"nameIdentifier": "1005804", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashi, Tatsuya"}], "nameIdentifiers": [{"nameIdentifier": "1005805", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aya, Sugyo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1005806", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Atsushi, Tsuji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1005807", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hitomi, Sudo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1005808", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanako, Takano", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1005809", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tatsuya, Higashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1005810", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/81281", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-12-11"}, "publish_date": "2020-12-11", "publish_status": "0", "recid": "81281", "relation": {}, "relation_version_is_last": true, "title": ["Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake"], "weko_shared_id": -1}
Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake
https://repo.qst.go.jp/records/81281
https://repo.qst.go.jp/records/812817ac4ec1c-8bcf-424b-8269-1a4dca5c32d0
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-12-11 | |||||
タイトル | ||||||
タイトル | Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Sugyo, Aya
× Sugyo, Aya× B Tsuji, Atsushi× Sudo, Hitomi× Takano, Kanako× Kusakabe, Moriaki× Higashi, Tatsuya× Aya, Sugyo× Atsushi, Tsuji× Hitomi, Sudo× Kanako, Takano× Tatsuya, Higashi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | In treatment-refractory cancers, tumor tissues damaged by therapy initiate the repair response; therefore, tumor tissues must be exposed to an additional burden before successful repair. We hypothesized that an agent recognizing a molecule that responds to anticancer treatment-induced tissue injury could deliver an additional antitumor agent including a radionuclide to damaged cancer tissues during repair. We selected the extracellular matrix glycoprotein tenascin-C (TNC) as such a molecule, and three antibodies recognizing human and murine TNC were employed to evaluate X-irradiation-induced changes in TNC uptake by subcutaneous tumors. TNC expression was assessed by immunohistochemical staining of BxPC-3 tumors treated with or without X-irradiation (30 Gy) for 7 days. Antibodies against TNC (3-6, 12-2-7, TDEAR) and a control antibody were radiolabeled with In and injected into nude mice having BxPC-3 tumors 7 days after X-irradiation, and temporal uptake was monitored for an additional 4 days by biodistribution and single-photon emission computed tomography with computed tomography (SPECT/CT) studies. Intratumoral distribution was analyzed by autoradiography. The immunohistochemical signal for TNC expression was faint in nontreated tumors but increased and expanded with time until day 7 after X-irradiation. Biodistribution studies revealed increased tumor uptake of all three In-labeled antibodies and the control antibody. However, a statistically significant increase in uptake was evident only for In-labeled 3-6 (35% injected dose (ID)/g for 30 Gy vs. 15% ID/g for 0 Gy at day 1, < 0.01), whereas limited changes in In-labeled TDEAR2, 12-2-27, and control antibody were observed (several % ID/g for 0 and 30 Gy). Serial SPECT/CT imaging with In-labeled 3-6 or control antibody provided consistent results. Autoradiography revealed noticeably stronger signals in irradiated tumors injected with In-labeled 3-6 compared with each of the nonirradiated tumors and the control antibody. The signals were observed in TNC-expressing stroma. Markedly increased uptake of In-labeled 3-6 in irradiated tumors supports our concept that an agent, such as an antibody, that recognizes a molecule involved in tissue injury repair, such as TNC, could enhance drug delivery to tumor tissues that have undergone therapy. The combination of antibody 3-6 coupled to a tumoricidal drug and conventional therapy has the potential to achieve better outcomes for patients with refractory cancer. | |||||
書誌情報 |
Cancers 巻 12, 号 12, p. 3652, 発行日 2020-12 |
|||||
出版者 | ||||||
出版者 | MDPI | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2072-6694 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 33291427 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3390/cancers12123652 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.mdpi.com/2072-6694/12/12/3652 |